Branchiogenic Hearing Loss Syndrome

Branchiogenic hearing loss syndrome refers to a group of birth conditions where parts of the neck and ear that grow from the branchial arches (structures that form the lower face, neck, and ear in the embryo) do not develop in the usual way. People can have small pits or cysts in the neck or in front of the ear, ear shape changes, and different types of hearing loss (sensorineural, conductive, or mixed). In BOR syndrome there may also be kidney problems; in BO syndrome and in the ultra-rare “branchiogenic deafness syndrome,” kidney problems are absent. The hearing loss can start at birth or later, can be stable or get worse, and can affect one or both ears. Doctors confirm the diagnosis with a careful physical exam, hearing tests, imaging of the ear, and genetic testing (commonly checking the EYA1, SIX1, and SIX5 genes). Nature+4NCBI+4MedlinePlus+4

Branchio-oto(-renal) spectrum disorders—better known as BOR/BO syndrome. In BOR, ear and neck differences occur with kidney anomalies; in BO, kidney problems are absent. Hearing loss may be conductive, sensorineural, or mixed, and it can vary from mild to profound, often from birth. The underlying biology most often involves changes in the EYA1, SIX1, or SIX5 genes that guide embryologic development of the branchial arches (neck), ears, and—when present—kidneys. NCBI+2MedlinePlus+2 During fetal development, “instruction proteins” from the EYA–SIX pathway talk to each other to build the side-of-the-neck tissues, the outer/middle/inner ear, and (in BOR) the kidneys. Variants in EYA1, SIX1, or SIX5 can scramble these signals, so ear parts may be shaped differently or not connect properly; kidney formation may also be affected in BOR. That is why people in the same family can have different kinds and severities of hearing loss and neck findings. NCBI+1

• Branchio-oto-renal (BOR) spectrum disorder and branchio-otic (BO) syndrome—common, well-documented genetic syndromes that feature branchial arch anomalies (neck cysts/fistulas), ear malformations, and high rates of hearing loss; BOR also has kidney problems, while BO does not. orpha.net+3NCBI+3MedlinePlus+3

• Branchiogenic deafness (hearing loss) syndrome (Mégarbané–Loiselet)—an ultra-rare description reported in one family that combines branchial and ear anomalies with congenital hearing loss without kidney abnormalities. Because it is so rare, clinicians typically manage patients using the well-studied BOR/BO framework. malacards.org+4orpha.net+4National Organization for Rare Disorders+4

Other names

• Branchiogenic deafness syndrome; Mégarbané–Loiselet syndrome (ultra-rare description). globalgenes.org+1

• Branchio-otic (BO) syndrome (branchial + ear features, no kidney findings). orpha.net

• Branchio-oto-renal (BOR) spectrum disorder (branchial + ear + possible kidney findings). NCBI+1

• Branchial arch anomalies with hearing loss (descriptive label used in reports). Nature

Types

1. BOR spectrum disorder – branchial + ear + kidney involvement; variable hearing loss pattern; autosomal dominant inheritance. NCBI+1

2. BO syndrome – branchial + ear involvement without kidney problems; hearing loss is common and may be mixed, conductive, or sensorineural. orpha.net

3. Branchiogenic deafness syndrome (Mégarbané–Loiselet) – extremely rare; branchial + ear malformations with congenital hearing loss, and no kidney issues; reported in one family. orpha.net+1

Causes

Below are common mechanisms and anatomy problems that explain hearing loss in BOR/BO and in the ultra-rare branchiogenic deafness description. Each item is a plain-language cause. (Most patients have more than one.)

1. Inner-ear development differences (cochlear dysplasia/Mondini-type changes)—the snail-shaped cochlea may have fewer turns or abnormal partitions, which makes sound conversion to nerve signals less efficient (sensorineural loss). NCBI+1

2. Enlarged/dilated vestibular aqueduct (EVA/DVA)—an enlarged fluid channel in the inner ear can cause fluctuating or progressive hearing loss, sometimes worse with head trauma or pressure changes. NCBI

3. Cochlear nerve hypoplasia or internal auditory canal (IAC) hypoplasia—the hearing nerve or the bony canal carrying it may be small, reducing sound signal transmission. malacards.org

4. Semicircular canal malformations—balance-organ changes often travel with cochlear abnormalities and can impair hearing as part of the same developmental pattern. NCBI

5. Ossicle malformations (malleus, incus, stapes)—tiny middle-ear bones may be misshapen or fixed, preventing normal sound conduction (conductive loss). NCBI

6. Stapes fixation or footplate abnormalities—the stapes may not move freely at the oval window, blocking sound movement into the inner ear. NCBI

7. Oval or round window atresia—the “windows” between the middle and inner ear can be missing or closed, stopping sound transfer (conductive loss). NCBI

8. External auditory canal atresia/stenosis—a narrow or closed ear canal reduces sound entry (conductive loss). NCBI

9. Eardrum (tympanic membrane) anomalies—abnormal thickness, position, or retraction makes the eardrum less effective at vibrating (conductive loss). NCBI

10. Chronic otitis media with effusion—fluid behind the eardrum is common in malformed ears and adds a conductive component. NCBI

11. Preauricular pits and sinus tracts with infections—recurrent infections around ear pits can temporarily worsen hearing by swelling or fluid, and signal underlying ear malformations. MedlinePlus

12. Middle-ear space hypoplasia—a small middle-ear cavity reduces the room for ossicles to move, limiting sound conduction. NCBI

13. Eustachian tube dysfunction—impaired pressure equalization promotes fluid and negative pressure, causing intermittent conductive loss. NCBI

14. Mixed hearing loss from combined inner- and middle-ear anomalies—very common in BOR/BO; patients often have both sensorineural and conductive elements. Nature

15. Progressive inner-ear damage over time—some people worsen in childhood/adolescence, especially with EVA; genetics likely drives vulnerability. NCBI

16. Craniofacial growth pattern differences—jaw and skull base relationships from branchial arch anomalies can secondarily affect ear mechanics. orpha.net

17. Cochlear aqueduct or perilymphatic abnormalities—atypical fluid pathways can change inner-ear pressure and hair-cell function. NCBI

18. Genetic variants in EYA1—the most frequent cause; alters a transcriptional co-activator crucial for ear/branchial development. Nature

19. Genetic variants in SIX1—homeobox gene changes disrupt ear and branchial patterning. Nature

20. Genetic variants in SIX5 or other loci—less common; contribute to the clinical spectrum. Nature

Symptoms

1. Hearing loss—present at birth or early childhood; one or both ears; can be stable or progressive; often mixed type. NCBI+1

2. Preauricular pits or tags—tiny openings or skin tags in front of the ear signal ear development differences. MedlinePlus

3. Ear shape changes (cupped or malformed pinnae)—outer-ear form varies and often accompanies hearing loss. orpha.net

4. Recurrent ear infections or fluid—due to structural differences or Eustachian tube dysfunction. NCBI

5. Branchial cysts or fistulas in the neck—soft lumps or small draining openings along the side of the neck. NCBI

6. Tinnitus (ringing)—especially with sensorineural components. NCBI

7. Balance problems or dizziness—inner-ear malformations can affect the vestibular system. NCBI

8. Speech or language delay—secondary to early hearing loss in children. NCBI

9. Ear canal narrowing or blockage—noticed on exam or when trying to clean ears/hear properly. NCBI

10. Family history of similar findings—autosomal dominant inheritance is common; each child of an affected parent has a 50% chance of inheriting the variant. NCBI

11. Facial/mandible minor differences—subtle jaw or facial asymmetries from branchial arch development. orpha.net

12. Neck infections—branchial cysts can get infected and painful. NCBI

13. Ear discharge—from infections or pits/sinuses. NCBI

14. Pressure sensitivity with hearing fluctuation—especially when EVA is present (worse after minor head injury or rapid pressure changes). NCBI

15. Kidney-related symptoms in BOR (not in BO/branchiogenic deafness)—some have abnormal urination, swelling, or high blood pressure; note these are absent in BO and in the ultra-rare Mégarbané–Loiselet description. NCBI+1

Diagnostic tests

Doctors choose tests based on age, symptoms, and family history. Results help confirm the syndrome, define ear anatomy, and plan care. NCBI

A) Physical examination

1. Head and neck inspection—looks for preauricular pits/tags, ear shape, and branchial cysts/fistulas; guides imaging and surgery. orpha.net+1

2. Otoscopy—checks the ear canal and eardrum for stenosis, atresia, retraction, or fluid. NCBI

3. Craniofacial and oral exam—assesses jaw alignment and palate; branchial arch patterns can affect these areas. orpha.net

4. Skin exam around ear pits/sinuses—looks for discharge or infection that could worsen hearing temporarily. NCBI

B) Manual bedside hearing tests

5. Whispered voice or finger rub—quick screen for asymmetry and gross hearing thresholds. NCBI

6. Tuning fork Rinne test—compares air vs bone conduction to detect conductive components. NCBI

7. Tuning fork Weber test—detects lateralization and helps separate conductive from sensorineural loss. NCBI

8. Tympanometry with pneumatic otoscopy (simple pressure test of eardrum mobility)—identifies middle-ear fluid, negative pressure, or ossicular fixation patterns. NCBI

C) Laboratory & pathological / genetic tests

9. Targeted multigene panel—tests EYA1, SIX1, SIX5 and related genes; confirms a molecular diagnosis and informs family counseling. Nature

10. Chromosomal microarray or exome sequencing—used if panel is negative or features are atypical; improves yield in syndromic hearing loss. NCBI

11. Renal function labs (BOR only)—urinalysis and serum creatinine to screen the kidney when BOR is suspected; not required for BO or for the ultra-rare kidney-negative entity. NCBI

12. Pathology of excised branchial cyst (when removed)—confirms branchial origin; helps exclude other lesions. NCBI

D) Electrodiagnostic audiology

13. Newborn hearing screen (OAE-based)—detects cochlear outer-hair-cell function soon after birth. NCBI

14. Diagnostic otoacoustic emissions (OAE)—clarifies cochlear function and separates sensorineural from conductive components. NCBI

15. Auditory brainstem response (ABR)—checks the hearing nerve and brainstem pathways; useful in infants or when behavioral tests are not reliable. NCBI

16. Behavioral audiometry (age-appropriate pure-tone/speech tests)—quantifies degree and type of loss and tracks progression over time. NCBI

E) Imaging tests

17. High-resolution CT (HRCT) of temporal bones—maps the ear canal, ossicles, oval/round windows, and middle-ear space; crucial for surgical planning. NCBI

18. MRI of internal auditory canals and brain—assesses the cochlear nerve, inner ear, and IAC size; complements CT. malacards.org

19. Renal ultrasound (BOR work-up)—screens the kidneys when BOR is suspected; not needed for BO or for the ultra-rare kidney-negative form. NCBI

20. Neck ultrasound or MRI for branchial lesions—defines the size and tract of cysts or fistulas before surgery. NCBI

Non-pharmacological treatments (therapies & other supports)

1) Early hearing detection and intervention (EHDI). Babies should be screened by 1 month, have diagnostic testing by 3 months, and start intervention by 6 months (the “1-3-6” rule). Early fitting of devices and family-centered therapy improves language and learning. CDC Stacks

2) Conventional hearing aids. Air-conduction hearing aids amplify sound and are tailored to the individual audiogram; they are first-line for many conductive or sensorineural losses in BOR/BO. Real-ear verification and routine follow-up optimize benefit. nidcd.nih.gov

3) Bone-anchored hearing devices (BAHD/BAHA). These transmit vibration through skull bone to bypass an atretic canal or malformed ossicles—useful in conductive/mixed loss or single-sided deafness. They may be worn on a softband in young children or implanted later. nidcd.nih.gov+1

4) Cochlear implant (CI) candidacy & counseling. If hearing aids or BAHA do not provide sufficient access to sound—especially with severe-to-profound sensorineural loss—CI can restore audibility and support speech development; candidacy is individualized in BOR/BO. PLOS

5) Auditory-verbal therapy (AVT). Structured listening-and-speaking therapy teaches families how to build language through hearing technologies; it complements aids/implants and improves real-world listening. nidcd.nih.gov

6) Speech-language therapy. Targets articulation, vocabulary, and comprehension gaps due to reduced audibility; school-based services align goals with academic demands. nidcd.nih.gov

7) Assistive listening devices (ALDs). Remote microphones/FM systems, classroom soundfield speakers, captioning, and phone/alerting tech improve signal-to-noise and access in school and work. nidcd.nih.gov

8) Educational accommodations. Preferential seating, captioned media, and individualized education plans (IEPs) reduce listening fatigue and improve learning outcomes. nidcd.nih.gov

9) Tinnitus management. Counseling, sound therapy, and hearing-aid features can lessen tinnitus awareness often associated with hearing loss. nidcd.nih.gov

10) Hearing conservation. Avoid loud noise; use well-fitting ear protection at concerts/work and limit headphone volumes to protect residual hearing. MDPI

11) Water & ear-canal care. With canal malformations or tubes, drying precautions and prompt care for drainage help prevent infections that can further reduce hearing. PMC

12) Cerumen (earwax) management. Professional removal prevents conductive block in narrow or atypical canals common in BOR/BO. SpringerOpen

13) Imaging-guided planning. Temporal-bone CT/MRI maps ear anatomy before surgery or implantation to avoid facial-nerve injury and to plan realistic outcomes. SpringerOpen

14) Genetic counseling. BOR/BO is usually autosomal dominant (each child has ~50% chance to inherit the variant); counseling supports informed family planning and testing of relatives. NCBI+1

15) Kidney monitoring (BOR). Because renal differences can accompany the ear findings in BOR, periodic kidney evaluation and blood pressure/urinalysis are prudent to protect long-term health. MedlinePlus

16) Psychosocial support. Peer groups, family counseling, and disability services reduce stigma and improve adherence with devices and therapy. nidcd.nih.gov

17) Vestibular therapy (if balance issues). Targeted exercises enhance balance and reduce falls when inner-ear differences cause dizziness or delayed motor milestones. nidcd.nih.gov

18) Transition planning. Teens with BOR/BO benefit from structured transition to adult audiology/ENT and (if indicated) nephrology care to maintain continuity. NCBI

19) Multidisciplinary clinic care. Coordinated ENT, audiology, genetics, speech-language, and (BOR) nephrology care aligns goals and reduces fragmented treatment. NCBI

20) Informed device selection. Some children do best with softband bone-conduction devices early, then transition to implantable systems or CI later; decisions are anatomy-, age-, and outcome-based. PMC

---

Drug treatments

There is no disease-specific drug that reverses BOR/BO hearing loss. Medicines below are commonly used for related ear conditions (e.g., acute otitis media, otorrhea, pain/fever), following FDA-approved labeling. Doses are examples from labels; clinicians individualize by age, weight, kidney function, local resistance, and allergy history. NCBI

1) Amoxicillin (AMOXIL). First-line oral antibiotic for many cases of acute otitis media (AOM) in appropriate patients. Label provides pediatric suspension strengths and dosing ranges; side effects include rash, diarrhea, and (rare) hypersensitivity. Timing with meals may not be necessary; complete the full course to reduce failure/relapse. FDA Access Data

2) Amoxicillin-clavulanate (AUGMENTIN). Adds β-lactamase inhibition for AOM due to organisms that make β-lactamase. Tablets and suspensions are labeled; GI upset is common, so taking at the start of a meal helps. FDA Access Data

3) Amoxicillin-clavulanate (AUGMENTIN ES-600). Pediatric high-amoxicillin formulation for AOM with risk factors (recent antibiotics, daycare, age ≤2 years). Label notes it is not indicated when S. pneumoniae MIC ≥4 µg/mL. FDA Access Data+1

4) Cefuroxime axetil (CEFTIN). Oral cephalosporin labeled for pediatric AOM (tablets or suspension). Useful for penicillin-allergic (non-anaphylactic) patients; typical adverse events are GI upset and rash. FDA Access Data+1

5) Cefdinir. Third-generation oral cephalosporin with AOM labeling; often used when amoxicillin isn’t suitable. Watch for red stools if taken with iron.

6) Cefpodoxime proxetil (VANTIN). Oral cephalosporin with AOM studies on the label; dosing commonly twice daily for 5–10 days depending on age/severity. FDA Access Data

7) Azithromycin. Macrolide with labeled AOM regimens (e.g., 5-day or single-dose options in some formulations). GI upset and QT prolongation are key cautions.

8) Clarithromycin (BIAXIN). Macrolide antibiotic; label documents penetration into middle-ear fluid. Metallic taste and GI effects are common. FDA Access Data+1

9) Ciprofloxacin-dexamethasone otic (CIPRODEX). Topical drops for AOM with tympanostomy tubes and for acute otitis externa; typical regimen is 4 drops twice daily for 7 days. Avoid contamination of dropper tip. FDA Access Data

10) Ciprofloxacin otic 0.2% (CETRAXAL). Single-use vials for acute otitis externa; do not use if allergic to quinolones. Warm the vial in the hand to reduce dizziness after instillation. FDA Access Data

11) Ciprofloxacin 6% otic suspension (OTIPRIO). For intratympanic administration in otitis media with effusion (e.g., during tube placement) and for acute otitis externa; administered by clinicians. FDA Access Data

12) Ciprofloxacin-fluocinolone otic (OTOVEL). Single-dose vials for AOM through tympanostomy tubes; combines antibacterial and anti-inflammatory actions. FDA Access Data

13) Neomycin-polymyxin B-hydrocortisone otic (CORTISPORIN/CASPORYN HC). For acute otitis externa; avoid if the eardrum is perforated due to ototoxicity risk. Hypersensitivity is possible. FDA Access Data+2FDA Access Data+2

14) Ofloxacin otic 0.3%. Quinolone eardrops for otitis externa and for AOM in children with tubes; typically safe with non-intact tympanic membranes.

15) Ibuprofen oral suspension (e.g., MOTRIN). For ear pain/fever in AOM; pediatric dose often 10 mg/kg every 6–8 h (max 40 mg/kg/day) per label. GI irritation and rare hypersensitivity can occur. FDA Access Data

16) Acetaminophen oral suspension. For pain/fever when NSAIDs are not preferred; follow weight-based label dosing and maximum daily limits to avoid liver injury.

17) Cipro HC otic (ciprofloxacin + hydrocortisone). Labeled for acute otitis externa in patients ≥1 year; contraindicated in quinolone or hydrocortisone hypersensitivity. FDA Access Data

18) Topical fluoroquinolone single-agent alternatives (e.g., ciprofloxacin 0.2% otic). Useful when steroid component is unwanted; follow label directions and complete the course. FDA Access Data

19) Pain control adjuncts (topical anesthetic ear drops where intact TM). Some OTC anesthetic drops can soothe pain when the eardrum is intact; always verify product indication. nidcd.nih.gov

20) Peri-operative antibiotics/analgesia (surgeon-directed). Around ear surgery (e.g., atresiaplasty/ossiculoplasty), clinicians follow institutional protocols for infection prophylaxis and pain control; medications are chosen according to operative findings and local policy. PMC+1

---

Dietary molecular supplements

No supplement has proven to reverse BOR/BO hearing loss. Some nutrients are being studied for general auditory health (antioxidants, magnesium, omega-3s). Discuss all supplements with your clinician, especially for children and in BOR with kidney issues. MDPI

1) Omega-3 fatty acids (EPA/DHA). Observational studies associate higher fish/omega-3 intake with lower risk of age-related hearing loss, and reviews outline plausible anti-inflammatory and vascular mechanisms in the cochlea. Typical supplement doses vary (often 0.5–1 g/day EPA+DHA for general health), but food sources are preferred; watch interactions (e.g., bleeding risk at high doses). PMC+2PubMed+2

2) Magnesium. RCTs and translational work suggest magnesium may lessen noise-induced hearing damage by stabilizing cochlear ion homeostasis and blood flow; typical study regimens used oral magnesium daily, but dosing and indications are not standardized for routine prevention. PubMed+1

3) Antioxidant vitamins (e.g., vitamins C/E). Animal and limited human data suggest antioxidants may attenuate oxidative stress after noise exposure; clinical evidence is mixed, so use is exploratory. MDPI+1

4) N-acetylcysteine (NAC). As a glutathione precursor, NAC is studied for potential otoprotection against noise/ototoxins via free-radical scavenging; robust routine-use evidence is lacking. onlinelibrary.wiley.com

5) Folate (vitamin B9). Low folate and high homocysteine have been linked to worse hearing in some studies, suggesting a vascular/neuronal mechanism; meet daily needs via diet or standard supplements. ajcn.nutrition.org

6) Vitamin B12. Observational data connect B12 sufficiency with healthier hearing thresholds; mechanism may involve myelin and homocysteine pathways. onlinelibrary.wiley.com

7) Zinc. Zinc participates in synaptic and antioxidant processes; small studies explore roles in tinnitus and infection immunity, but routine use for hearing remains unproven. MDPI

8) Coenzyme Q10 (ubiquinone). Experimental models show Q10 can mitigate cochlear oxidative injury; human data are limited. Consider only as an adjunct with clinician guidance. PMC

9) Vitamin D (if deficient). Adequate vitamin D supports bone/ossicle and immune health; correct deficiency per general guidelines (not as a hearing-loss cure). MDPI

10) General antioxidant-rich diet pattern. Diets rich in fruits, vegetables, fish, nuts, and whole grains may support cochlear microcirculation and reduce oxidative stress, aligning with broader cardiovascular benefits that also matter to inner-ear health. Frontiers

---

Immunity-booster / regenerative / stem-cell drugs

There are no FDA-approved stem-cell or regenerative drugs for hearing loss. FDA warns consumers about clinics marketing unapproved stem-cell products (including “exosomes”) for many conditions; such products can cause serious harm. Approved cell/gene therapies today treat other diseases—not hearing loss. If you see offers of stem-cell “cures” for deafness, treat them as unproven. Consider regulated clinical trials instead. U.S. Food and Drug Administration+2U.S. Food and Drug Administration+2

Research note: Early human studies of gene therapy for certain monogenic deafness (e.g., DB-OTO for OTOF-related loss) are underway and show encouraging signals, but these are investigational and not approved for BOR/BO. cgtlive.com+1

---

Surgeries

1) Tympanostomy tubes. Tiny ear tubes are placed through the eardrum to ventilate the middle ear, reduce infections/fluid, and improve hearing when persistent effusion or recurrent AOM limits sound transmission. They also allow safe delivery of certain ear drops. FDA Access Data

2) Atresiaplasty (canal reconstruction). For congenital aural atresia/stenosis, surgeons drill and line a new ear canal and may reconstruct the eardrum to open an air-conduction path. Because anatomy and outcomes vary, many teams favor bone-conduction solutions first, reserving surgery for selected candidates. PMC+1

3) Ossiculoplasty (middle-ear bone repair/replacement). Rebuilds the ossicular chain when bones are malformed, fixed, or discontinuous; prostheses (PORP/TORP) aim to close the air-bone gap and improve hearing. Success depends on middle-ear health and anatomy. NCBI+1

4) Bone-anchored hearing system implantation. A small titanium fixture integrates with bone; a processor sends vibrations directly to the inner ear, bypassing the outer/middle ear—helpful for atresia or ossicular problems. Choice of percutaneous vs. transcutaneous systems depends on age/anatomy. nidcd.nih.gov+1

5) Cochlear implant. When severe sensorineural loss prevents meaningful benefit from aids/BAHA, a CI bypasses damaged hair cells to directly stimulate the auditory nerve; intensive therapy follows to build listening and speech. PLOS

---

Preventions

1. Newborn & early-childhood hearing checks (1-3-6 timeline) and prompt intervention. CDC Stacks

2. Noise protection at work, school, and recreation (hearing protection and safe listening). MDPI

3. Avoid ototoxic drugs when alternatives exist (e.g., caution with aminoglycosides/cisplatin; if needed, monitor).

4. Up-to-date vaccines to lower ear-infection risk per pediatric schedules. nidcd.nih.gov

5. Prompt treatment for ear infections or persistent ear drainage. FDA Access Data

6. Regular audiology/ENT follow-up to adjust devices and monitor changes. PLOS

7. Kidney screening in BOR to prevent unrecognized renal complications. MedlinePlus

8. Education on device care (drying kits, battery safety, processor hygiene). nidcd.nih.gov

9. School accommodations to reduce listening strain and improve academic access. nidcd.nih.gov

10. Healthy lifestyle (sleep, exercise, diet quality) that supports vascular and neural health relevant to the cochlea. Frontiers

---

When to see a doctor

Seek evaluation now if your child misses newborn screening, fails a rescreen, has delayed speech, struggles to hear in quiet or noise, has recurrent ear infections or persistent ear discharge, or any sudden change in hearing. Newborns should be screened by 1 month; confirmed diagnosis by 3 months; intervention by 6 months. Adults with progressive difficulty hearing conversations, tinnitus, imbalance, or ear fullness also need prompt ENT/audiology care. Families with known BOR/BO should consider genetic counseling and regular kidney checks (BOR). CDC Stacks+1

---

What to eat” and “what to avoid

Eat more of:

1. Fish (omega-3s) like salmon/sardines 1–2×/week to support vascular and anti-inflammatory pathways linked to healthier hearing in population studies. PMC+1
2. Leafy greens/legumes (folate) to maintain homocysteine balance relevant to cochlear blood flow. ajcn.nutrition.org
3. Nuts/seeds/whole grains for magnesium and antioxidant polyphenols that may help cochlear resilience. PubMed
4. Colorful fruits & vegetables for antioxidants that counter oxidative stress in the inner ear. MDPI
5. Adequate hydration to support inner-ear fluid homeostasis (general health guidance). MDPI

Limit/avoid:

1. Excessive noise (not food, but the biggest preventable risk). MDPI
2. Unregulated supplements/“ear cures.” Choose evidence-based products and discuss with your clinician, especially in children and those with kidney issues. U.S. Food and Drug Administration
3. Unnecessary ototoxic medications (when alternatives exist); if unavoidable, ask about monitoring.
4. Heavily salted ultraprocessed foods if you notice fluctuating ear fullness—some people are salt-sensitive (general ENT practice; individualize). nidcd.nih.gov
5. Very high-dose single-nutrient megasupplements without supervision (possible interactions/side effects). MDPI

---

Frequently asked questions

1) Is “branchiogenic hearing loss syndrome” the same as BOR/BO?
Yes—clinicians typically mean branchio-oto-renal/branchio-otic spectrum disorders. The ear/neck pattern and hearing loss are the same; BOR includes kidney anomalies, BO does not. MedlinePlus

2) What causes it?
Variants in EYA1, SIX1, or SIX5 disrupt embryologic instructions for neck/ear (and kidney in BOR) development. NCBI

3) What kind of hearing loss occurs?
Any type—conductive (outer/middle ear), sensorineural (inner ear), or mixed—ranging from mild to profound; one or both ears may be involved. NCBI

4) Is there a medicine that cures the hearing loss?
No. Drugs treat associated infections/inflammation or pain/fever but do not fix the structural differences. Hearing devices and, in selected cases, surgery or cochlear implantation provide access to sound. PLOS

5) Do supplements fix it?
No. Some nutrients (omega-3s, magnesium, antioxidants) have supportive evidence for general cochlear health, mainly in noise or aging contexts—not as cures for BOR/BO. PMC+1

6) Are stem-cell therapies available?
No FDA-approved stem-cell treatments exist for hearing loss. Be wary of clinics selling unapproved products; consider regulated trials instead. U.S. Food and Drug Administration

7) Will my child need surgery?
Not always. Many children do well with hearing aids or bone-conduction devices; surgery (atresiaplasty/ossiculoplasty) is reserved for selected anatomies and goals. PMC+1

8) Is cochlear implantation an option?
Yes, when severe sensorineural loss prevents benefit from hearing aids. Outcomes depend on inner-ear/nerve integrity and therapy engagement. PLOS

9) Should our family get genetic counseling?
Yes. BOR/BO is usually autosomal dominant; each child of an affected parent has ~50% chance of inheriting the variant. Counseling helps with testing and planning. europepmc.org

10) How often should hearing be checked?
In infancy: follow the 1-3-6 timeline; thereafter: at least annually in childhood, and sooner if any change is noticed or infections are frequent. CDC Stacks

11) What about school?
Ask for classroom remote microphone systems, captioned materials, and individualized supports to reduce listening fatigue and improve learning. nidcd.nih.gov

12) Can infections make hearing worse?
Yes—middle-ear fluid and recurrent AOM can temporarily or permanently worsen hearing, which is why prevention and prompt care matter. FDA Access Data

13) Are bone-anchored devices safe for kids?
They are widely used; candidacy considers age/bone thickness and whether a non-surgical softband can bridge early years. nidcd.nih.gov+1

14) Will hearing get worse over time?
It can be stable or progressive; regular follow-up ensures device re-programming or timely candidacy for other options if needs change. NCBI

15) What’s coming next?
Research in gene therapy and targeted inner-ear treatments is advancing, but these remain investigational and not yet available for BOR/BO. cgtlive.com

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 02, 2025.